Newsroom

Sorted by: Latest

-

Advocacy Unveils Promptless, Revolutionizing AI Litigation Platform by Putting Humans in Control

SAN FRANCISCO--(BUSINESS WIRE)--Advocacy, the first context-driven AI platform for litigation, today released Promptless, a major expansion of its matter-centric technology that delivers AI support to litigation teams proactively—without prompting—while also giving a new level of primacy to human judgment in an AI litigation platform. Built on Advocacy’s existing document review, drafting, and collaboration features, Promptless eliminates the need for litigators to start AI-assisted work with a...
-

Securities Fraud Investigation Into Tigo Energy, Inc. (TYGO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tigo Energy, Inc. (“Tigo” or the “Company”) (NASDAQ: TYGO) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON TIGO ENERGY, INC. (TYGO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On August 4,...
-

NYSE to Commence Delisting Proceedings Against SilverBox Corp IV (SBXD)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange LLC (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the three securities enumerated below (“Securities”) of SilverBox Corp IV (the “Company”) from the NYSE. Trading in the Company’s Securities will be suspended immediately. Symbol Description SBXD Class A ordinary shares, par value $0.0001 per share SBXDU Units, each consisting of one Class A ordinary share, $0.0001 p...
-

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions wit...
-

MVB Bank Announces Strategic Partnership With DingoBlu Financial

FAIRMONT, W.Va.--(BUSINESS WIRE)--DingoBlu Financial, Inc., a financial technology company developing a mobile-first platform for personal financial products, today announced a strategic partnership with MVB Bank, Inc. The partnership represents an important milestone as DingoBlu prepares to introduce its platform and suite of financial products.DingoBlu is a Visa fintech partner, and its debit card program will run on the Visa network through its bank partner, MVB Bank. Through the relationship...
-

The New York Times Company Declares Regular Quarterly Dividend

NEW YORK--(BUSINESS WIRE)--The New York Times Company’s Board of Directors today declared a regular quarterly dividend of $0.23 per share on the Company’s Class A and Class B common stock. The dividend is payable on October 22, 2026, to shareholders of record as of the close of business on October 7, 2026. The New York Times Company (NYSE: NYT) is a trusted source of quality, independent journalism whose mission is to seek the truth and help people understand the world. With more than 13 millio...
-

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

TOKYO--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions with the U...
-

HAFNIA LIMITED: Public Filing of Prospectus Supplement in Connection with the Offering

SINGAPORE--(BUSINESS WIRE)--Reference is made to the stock exchange announcement published by Hafnia Limited ("Hafnia" or the "Company”, OSE: HAFNI, NYSE: HAFN) on 24 September 2026 regarding the successful completion and pricing of an offering of 35,488,875 ordinary shares in the Company, raising gross proceeds of the NOK equivalent of approximately USD 300 million (the “Offering”). The Company has today filed a prospectus supplement pursuant to the Company’s effective shelf registration state...
-

Elmhurst 1925 Launches Clean Protein™ in Canada, Redefining Ready-to-Drink Nutrition

TORONTO--(BUSINESS WIRE)--Elmhurst® 1925, maker of the world’s finest plant-based foods and beverages, introduces Clean Protein™ in the Canadian market. The ready-to-drink plant-based protein beverage delivers 27g of complete protein with just 190 calories and absolutely no gums, seed oils, or artificial sweeteners, underscoring Elmhurst’s commitment to simple ingredients, superior performance, and the cleanest ingredient lists in an entirely new category for the brand – RTD protein. Anchoring...
-

TNS to Tackle Cross-Channel Fraud and Customer Trust in Two Sessions at CFCA Fall Educational 2026

RESTON, Va.--(BUSINESS WIRE)--Communications fraud rarely stays in one lane. Bad actors move across voice, messaging, email, applications and social media – spoofing financial institutions’ phone numbers to impersonate them and defraud customers, and exploiting the fact that the intelligence needed to stop them is often scattered across platforms, companies, industries, countries and continents. The result is a widening trust gap where consumers have grown wary of even legitimate outreach from...